Biotech
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Del.icio.us
- Digg
- StumbleUpon
-
PLAY BEAT THE STREET GAME NOW
Discovery Labs DSCO said Friday that the Food and Drug Administration did not approve its Surfaxin for the prevention of respiratory distress syndrome (RDS) in premature infants, but deemed it approvable in the future under certain undisclosed conditions. Shares of the Warrington, Pa.-based biotech company, which traded higher over the course of the week on the drug's approval prospects, plummeted $1.35, or 46.6%, to $1.55 in recent premarket trading Friday. Manufacturing and quality control issues have stymied two prior attempts at the drug's approval, although the company remarked in Friday's announcement that its manufacturing facility in Totowa, N.J., had passed the agency's pre-approval inspection successfully. The company also said it had finalized labeling discussions with the FDA. The company, which didn't disclose what the approvable conditions regard, said it will assess the FDA's letter and will provide an update early next week.
Shares are falling 8% as the agency turns down an application for a new cholesterol treatment.
But factoring out acquisition costs, the drugmaker beats Wall Street's first-quarter estimates.
The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price.
Apple and AT&T were among the most searched stocks on TheStreet.com Friday. Here's what Cramer had to say about them recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Looking for deep value with Defiance Asset Management, polling big investors about where the market's headed, plus much more.
See who made what calls.
3 Stocks I Saw On TVDan Fitzpatrick examines three stocks viewed on Fast Money and Mad Money Today's stocks include Deere & Co., Petrobras and MBIA
TheStreet.com Ratings checks in on First Community Bancorp and First Niagara Financial Group two months after recommending the stock.
Take-Two's latest hit receives a perfect score from industry reviewers.
- Cramer's 'Mad Money' Recap: Mad Money's Rally Playbook
- The Polycarbonate Price Cut
- CalPERS Pushes for Clean House at Standard Pacific
- Investing in China: What You Need to Know
- Coming Week: 'Glimmer of Hope'
- Top Stocks With Insider Buying, Buybacks
- New Solar ETF Helps Spread Sector's Risk
- Feuerstein's Biotech-Stock Mailbag
- Need to Own Energy? Here's How to Do It
- My Company Doesn't Provide Health Insurance (Gulp!)
Sponsored by:
RSS
